Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics

Sage Therapeutics, Inc. (SAGE): $42.91

0.46 (+1.08%)

POWR Rating

Component Grades













Add SAGE to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where SAGE ranks best; there it ranks ahead of 48.44% of US stocks.
  • The strongest trend for SAGE is in Growth, which has been heading down over the past 179 days.
  • SAGE ranks lowest in Stability; there it ranks in the 13th percentile.

SAGE Stock Summary

  • The ratio of debt to operating expenses for SAGE THERAPEUTICS INC is higher than it is for about only 6.9% of US stocks.
  • With a price/sales ratio of 326.56, SAGE THERAPEUTICS INC has a higher such ratio than 98.74% of stocks in our set.
  • SAGE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.34% of US stocks.
  • If you're looking for stocks that are quantitatively similar to SAGE THERAPEUTICS INC, a group of peers worth examining would be CDXS, MRNS, VERU, APLS, and RMBS.
  • SAGE's SEC filings can be seen here. And to visit SAGE THERAPEUTICS INC's official web site, go to

SAGE Valuation Summary

  • In comparison to the median Healthcare stock, SAGE's price/earnings ratio is 121.24% lower, now standing at -4.8.
  • Over the past 105 months, SAGE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for SAGE.

Stock Date P/S P/B P/E EV/EBIT
SAGE 2023-03-17 332.1 2.0 -4.8 -4.5
SAGE 2023-03-16 339.1 2.1 -4.9 -4.6
SAGE 2023-03-15 336.6 2.1 -4.9 -4.6
SAGE 2023-03-14 342.2 2.1 -4.9 -4.7
SAGE 2023-03-13 336.9 2.1 -4.9 -4.6
SAGE 2023-03-10 307.4 1.9 -4.4 -4.1

SAGE Growth Metrics

    The 3 year revenue growth rate now stands at -93.05%.
  • Its year over year net income to common stockholders growth rate is now at -176%.
  • The 5 year cash and equivalents growth rate now stands at 38.2%.
SAGE's revenue has moved down $1,003,000 over the prior 34 months.

The table below shows SAGE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 7.686 -460.036 -532.784
2022-09-30 6.464 -430.605 -510.35
2022-06-30 6.165 -380.566 -503.198
2022-03-31 6.307 -376.896 -484.183
2021-12-31 6.308 -378.182 -457.892
2021-09-30 1,113.852 730.29 641.715

SAGE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SAGE has a Quality Grade of C, ranking ahead of 62.22% of graded US stocks.
  • SAGE's asset turnover comes in at 0.544 -- ranking 73rd of 681 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SESN are the stocks whose asset turnover ratios are most correlated with SAGE.

The table below shows SAGE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.544 0.999 0.571
2021-06-30 0.637 0.999 0.746
2021-03-31 0.767 0.999 0.960
2020-12-31 0.954 0.999 1.092
2020-09-30 0.008 0.907 -0.813
2020-06-30 0.009 0.929 -0.814

SAGE Price Target

For more insight on analysts targets of SAGE, see our SAGE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.11 Average Broker Recommendation 1.66 (Moderate Buy)

SAGE Stock Price Chart Interactive Chart >

Price chart for SAGE

SAGE Price/Volume Stats

Current price $42.91 52-week high $49.56
Prev. close $42.45 52-week low $27.36
Day low $41.51 Volume 306,300
Day high $43.04 Avg. volume 523,314
50-day MA $43.51 Dividend yield N/A
200-day MA $39.38 Market Cap 2.56B

Sage Therapeutics, Inc. (SAGE) Company Bio

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.

SAGE Latest News Stream

Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream

Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Sage Therapeutics to Present at the Stifel 2023 CNS Days

CAMBRIDGE, Mass., March 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET.

Yahoo | March 22, 2023

Sage Therapeutics Appoints Jessica Federer to Board of Directors

CAMBRIDGE, Mass., March 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.

Yahoo | March 16, 2023

Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?

Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | March 14, 2023

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | March 8, 2023

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

CAMBRIDGE, Mass., March 08, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Yahoo | March 8, 2023

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo 1.71%
3-mo 11.60%
6-mo 11.45%
1-year 27.56%
3-year 46.15%
5-year -72.53%
YTD 12.51%
2022 -10.34%
2021 -50.83%
2020 19.84%
2019 -24.64%
2018 -41.84%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8625 seconds.